An observational study in Daptomycin, Real-world Study and Intensive Care Unit, sponsored by West China Hospital. Completed at 1 site in China. Open to participants aged 1 Year to 100 Years. Per ClinicalTrials.gov, last updated 2022-07-25.
Sponsored by West China Hospital · Observational
Analyze the effectiveness and safety of Daptomycin(Jiangsu Hengrui Medicine Co., Ltd) in Gram-positive infections in Chinese Intensive Care Units by using the real-world data platform, https://rws.scccmqc.com. Patients who received at least one dose of Daptomycin between 2016 to 2021 are eligible.
West China Hospital is the lead sponsor of 483 studies on the registry; 240 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient who are suspected of Gram-positive infection in the Intensive Care Units.
Exclusion Criteria:
Patient who receive at least one dose of daptomycin
Other: No intervention
No intervention
mortality
death
Time frame: 30 days
Cure Rate
clinical and microbiological effectiveness
Time frame: 30 days
Number of participants with treatment-related adverse events
organ dysfunction，allergy，creatine kinase levels，eosinophilic pneumonia，etc.
Time frame: 30 days
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
West China Hospital